Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-11-17

Clinical Trial Update: An Open-Label Safety Study of A-101 Solution [Phase 3]

View source ↗

Summary

Phase 3 open-label safety study of A-101 Solution completed; results posted in 2017 for seborrheic keratosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • A-101 Solution

Snippet

Sponsor: Aclaris Therapeutics, Inc. | Conditions: Seborrheic Keratosis | Phase 3 | Status: COMPLETED | Results posted: 2017-11-17